The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

BPX-201 Vaccine for Chemotherapy-Naïve mCRPC

Thomas E. Hutson, DO, PharmD
Published Online: 3:16 PM, Tue June 10, 2014
Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses a phase I study of BPX-201 vaccine plus AP1903 for chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

Clinical Pearls

  • BPX-201 is novel, second-generation, autologous antigen presenting cell-based vaccine.
  • In a previous phase I trial, this has proven to be a potent approach to vaccination against prostate cancer.
  • There is hope that this approach will lead to both survival benefit and real-time benefit in the form of tumor responses and PSA reductions.
  • To date, 6 patients have been enrolled in the trial and no dose-limiting toxicities have been observed.

<<< Back to "Immunotherapy News from ASCO"

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.